MIAMI BEACH, Fla., April 25, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (“AirSculpt”) (NASDAQ: AIRS) an industry leader and provider of premium body contouring procedures, today announced it will report first quarter 2025 financial results before market open on Friday, May 2, 2025, to be followed by a conference call on the same day at 8:00 a.m. Eastern Time.
The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13753206 or by clicking this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the AirSculpt Technologies website at https://investors.airsculpt.com. A replay of the webcast will be available for approximately 90 days.
About AirSculpt
AirSculpt is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin, while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results.
Investor Contact:
Allison Malkin
Partner, ICR Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.43 |
Daily Change: | -0.59 -19.54 |
Daily Volume: | 1,152,580 |
Market Cap: | US$140.650M |
May 02, 2025 December 17, 2024 November 08, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load